This document provides an overview of maternal mortality trends and measurement in the Americas. It discusses:
1) Issues with inconsistent definitions and measurement of maternal deaths across countries.
2) Maternal mortality trends have declined in some countries but increased in others from 2008-2009, possibly due to the pandemic.
3) There is heterogeneity across the region - some countries have strong political commitment and monitoring systems while others struggle with underreporting and inconsistent data. Standardizing definitions and measurement approaches could help improve monitoring of progress on reducing maternal mortality from 1990-2010 levels.
Fiona McKay-Diagnóstico prenatal no invasivo y diagnóstico genético reproductivoFundación Ramón Areces
Los días 8 y 9 de junio de 2017 organizamos en la Fundación Ramón Areces con el Ciberer y la Fundación Jiménez Díaz un simposio internacional sobre 'Diagnóstico prenatal no invasivo y diagnóstico genético reproductivo'. Coordinado por la doctora Ana Bustamante, del servicio de Genética del Hospital Universitario Fundación Jiménez Díaz, tuvo como objetivo mostrar los últimos avances en el campo de la genética reproductiva a nivel preimplantacional, prenatal, e, incluso, preconcepcional.
115 countries lack data to determine maternal deaths or have no data at all. The lack of vital event data is a major concern that prevents the implemetation of the most adequate programmes and policies to tackle maternal deaths. To make women count, we should first start counting them.
Fiona McKay-Diagnóstico prenatal no invasivo y diagnóstico genético reproductivoFundación Ramón Areces
Los días 8 y 9 de junio de 2017 organizamos en la Fundación Ramón Areces con el Ciberer y la Fundación Jiménez Díaz un simposio internacional sobre 'Diagnóstico prenatal no invasivo y diagnóstico genético reproductivo'. Coordinado por la doctora Ana Bustamante, del servicio de Genética del Hospital Universitario Fundación Jiménez Díaz, tuvo como objetivo mostrar los últimos avances en el campo de la genética reproductiva a nivel preimplantacional, prenatal, e, incluso, preconcepcional.
115 countries lack data to determine maternal deaths or have no data at all. The lack of vital event data is a major concern that prevents the implemetation of the most adequate programmes and policies to tackle maternal deaths. To make women count, we should first start counting them.
stillbirth based on Williams Obstetrics, 25th Edition,2019 is 35th chapter of this book
this slide is so useful for medical student$resident of gynecology in all of the world
for new slide from every part of medical please contact with me
this slide has all of figure and important text from williams book
20160219 - F. Grati - Toma - Maternal MalignanciesRoberto Scarafia
Origin of cfDNA testing (Synonyms – NIPT or NIPS) for fetal aneuploidies
Performances of cfDNA testing for fetal aneuploidies
Maternal malignancies as a possible source for false positive cfDNA results
How to detect when the cause of FP result is a maternal malignancy
Implications for genetic counseling
Please note this presentation was presented on 10 April 2013 at the College of Medicine at the University of Illinois at Chicago, sponsored by the Center for Global Health. While you can see what I displayed, you cannot hear what I said, and I am sorry about that. Please let me know how I may be able to be of help to you in your work, or how I may be able to get a transcript to you.
Cheers, Chris
http://about.me/DrChrisStout
stillbirth based on Williams Obstetrics, 25th Edition,2019 is 35th chapter of this book
this slide is so useful for medical student$resident of gynecology in all of the world
for new slide from every part of medical please contact with me
this slide has all of figure and important text from williams book
20160219 - F. Grati - Toma - Maternal MalignanciesRoberto Scarafia
Origin of cfDNA testing (Synonyms – NIPT or NIPS) for fetal aneuploidies
Performances of cfDNA testing for fetal aneuploidies
Maternal malignancies as a possible source for false positive cfDNA results
How to detect when the cause of FP result is a maternal malignancy
Implications for genetic counseling
Please note this presentation was presented on 10 April 2013 at the College of Medicine at the University of Illinois at Chicago, sponsored by the Center for Global Health. While you can see what I displayed, you cannot hear what I said, and I am sorry about that. Please let me know how I may be able to be of help to you in your work, or how I may be able to get a transcript to you.
Cheers, Chris
http://about.me/DrChrisStout
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Maternal Mortality Panorama in the Americas
1. Maternal Mortality Panorama
in the Americas
Fatima Marinho, MD, MPH, PhD
Health and Analysis (HSD/HA)
Pan American Health Organization (PAHO/WHO)
2. Topics
• Background
– Quality of maternal death information in The Americas
Issues with definition and measurement
• Maternal mortality trend by selected countries
• Point for discussion
3. Concepts and definitions
ICD-10 - Maternal death definition
The death of a woman while pregnant or within 42 days of
termination of pregnancy, irrespective of the duration and
site of the pregnancy, from any cause related to or
aggravated by the pregnancy or its management but not
from accidental or incidental causes.
This definition allows identification of maternal deaths, based on their causes
as either direct or indirect.
4. Direct obstetric Indirect obstetric
deaths deaths
• those resulting from obstetric • those resulting from previous
complications of the pregnant existing disease, or diseases
state (pregnancy, delivery, that developed during
and postpartum), from pregnancy,
interventions, omissions, • and which were not due to
incorrect treatment, or from a direct obstetric causes but
chain of events resulting from aggravated by physiological
any of the above. effects of pregnancy.
for example: for example:
• haemorrhage, deaths due to aggravation of an
• pre-eclampsia/eclampsia existing cardiac or renal disease
are indirect obstetric deaths.
• or those due to complications
of anaesthesia or caesarean
section are classified as direct
obstetric deaths
5. Opportunities and options for Measuring
Maternal Mortality
Empirical measurement Analytical
Routine Opportunities Special Opportunities
Birth-death record
4. Surveys* 5. Surveillance*
1.Death A) Household survey linkage: to find
3. Decennial A) Demographic
Registration asking about deaths in Surveillance Systems Maternal deaths
Census* Household
A)Civil B) Prospective study
Registration** B) Indirect Sisterhood – Dual method
B)Sample Vital household survey asking C) Sample Vital or capture –
Registration*/ 2. Health about deaths of sisters, Registration, with recapture:
Facility Verbal
** without dates Autopsy (SAVVY) corrects for
Statistics** under - reporting
C) Direct Sisterhood – D) Active surveillance
household survey, of reproductive
asking about deaths of age female deaths UN models:
sisters, with dates Estimate levels
E) Active surveillance of
pregnancy-related or of maternal
D) Sampling at Service
Sites (SSS) – using maternal deaths mortality using
(Confidential Enquiries) regression
direct sisterhood method
6. RAMOS*: In-depth review of reproductive-age female deaths identified from
routine &/or special opportunities, & follow-up investigation of maternal deaths
Colour key: Green = longitudinal & continuous capture of deaths; Red= cross-sectional capture; Grey = mixed capture; Teal= no new
capture of deaths
* Deaths actively sought by measurement ** Deaths passively recorded, as dependent on relatives or health providers to notify death
6. How many maternal deaths occur annually
in the Region? • 8000 deaths (mortality database)
• 12 000 deaths (estimated)
VEN
USA
URY
TTO
OMS UNICEF, UNFPA, WB
WHO,
SUR
SLV OPS(país)
PAHO (countries)
PRY
PRI
PER
PAN
NIC
MEX
JAM
HND
GUY
GTM
ECU
DOM
CUB
CRI
COL
CHL
CAN
BRB
BRA
BOL
BLZ
BHS
ARG Maternal mortality Ratio (MMR 100 000 lb)
0.0 50.0 100.0 150.0 200.0 250.0 300.0
Source: PAHO/WHO. Mortality Information System
7. Which are the main causes of maternal
deaths?
Source: PAHO/WHO. Mortality Information System
8. Tendencia de la razón de mortalidad materna en los
países con serie temporal disponible.
Región de las Américas, 2000 a 2009
9. Infant and Maternal Mortality Rates are higher in
more unequal countries
Maternal Mortality Ratio
250
200
Infant Mortality Ratio
-2
6
0
150
60 100
50 50
b
2
0
1
]
,
l
40
0
M
m
o
d
p
n
e
a
y
r
t
[
,
i
l
30 0 10 20 30 40
Highest 20%/Lowest 20% income ratio [Ratio] 2002-2006
20
10
m
In Bolivia the highest 20% receives 36
m
n
h
d
6
0
2
1
e
a
E
y
s
r
t
o
b
p
n
0
1
e
)
(
a
y
l
i
r
t
]
[
f
I
,
i
l
0
0 10 20 30 40 times the lowest 20%
Highest 20%/Lowest 20% income ratio [Ratio] 2002-2006
More inequality is related to higher
Source: PAHO Basic Indicators infant and maternal mortality rates
10. Change in Maternal Mortality in 2009
in countries with decling tendencies in
previous years
2008 2009 % Cambio
Argentina 322 422 31.1
Brasil 1679 1878 11.9
Ecuador 165 208 26.1
Mexico 1135 1229 8.3
Paraguay 115 128 11.3
Cuba 57 66 15.8 Pandemic
Republica Dominicana* 190 202 6.3
Impact?
Uruguay* 4 16 300.0
Chile 41 43 4.9
Costa Rica 19 10 -47.4
El Salvador 18 14 -22.2
Guatemala 335 340 1.5
Panama 41 29 -29.3
Source: PAHO/WHO. Mortality Information System
*Rep. Dominicana y Uruguay dato reportado por la vigilancia
11. Brasil
600
Abortion
500 Oedema, proteinuria and hypertensive
disorders in pregnancy, childbirth and the
puerperium
Haemorrhage in pregnancy, childbirth and the
puerperium
400
Maternal deaths
Sepsis and another puerperal infecctions
Complications predominantly related to the
300 pregnacy and childbirth
Complications predominantly related to the
puerperium
200 Indirect obstetric deaths
Obstetric death of unspecified cause
100
Maternal Deaths from from any obstetric
cause occurring more than 42 days but less
than one year after delivery and sequelae
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Source: PAHO/WHO. Mortality Information System
12. Brasil
Maternal mortality: proportion by causes and MMR
Source: PAHO/WHO. Mortality Information System
14. Mexico
500
Abortion
450
Oedema, proteinuria and hypertensive
disorders in pregnancy, childbirth and the
400 puerperium
Haemorrhage in pregnancy, childbirth and
Maternal deaths
350 the puerperium
Sepsis and another puerperal infecctions
300
250 Complications predominantly related to the
pregnacy and childbirth
200 Complications predominantly related to the
puerperium
150 Indirect obstetric deaths
100
Obstetric death of unspecified cause
50
Maternal Deaths from from any obstetric
cause occurring more than 42 days but less
0 than one year after delivery and sequelae
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Source: PAHO/WHO. Mortality Information System
15. Mexico
Maternal mortality: proportion by causes and MMR
Source: PAHO/WHO. Mortality Information System
17. Ecuador
Abortion
90
Oedema, proteinuria and hypertensive
80
disorders in pregnancy, childbirth and
the puerperium
70 Haemorrhage in pregnancy, childbirth
and the puerperium
60 Sepsis and another puerperal infecctions
Maternal deaths
50
Complications predominantly related to
the pregnacy and childbirth
40
Complications predominantly related to
the puerperium
30
Indirect obstetric deaths
20
Obstetric death of unspecified cause
10
Maternal Deaths from from any obstetric
0 cause occurring more than 42 days but
less than one year after delivery and
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 sequelae
Source: PAHO/WHO. Mortality Information System
18. Chile
20
Abortion
18
Oedema, proteinuria and hypertensive
16 disorders in pregnancy, childbirth and the
puerperium
Haemorrhage in pregnancy, childbirth
14 and the puerperium
Maternal deaths
12 Sepsis and another puerperal infecctions
10
Complications predominantly related to
the pregnacy and childbirth
8
Complications predominantly related to
the puerperium
6
Indirect obstetric deaths
4
Obstetric death of unspecified cause
2
0 Maternal Deaths from from any obstetric
cause occurring more than 42 days but
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 less than one year after delivery and
sequelae
Source: PAHO/WHO. Mortality Information System
19. Guatemala
160
Abortion
140
Oedema, proteinuria and hypertensive
disorders in pregnancy, childbirth and the
puerperium
120
Haemorrhage in pregnancy, childbirth and the
puerperium
100 Sepsis and another puerperal infecctions
Maternal deaths
Complications predominantly related to the
80 pregnacy and childbirth
Complications predominantly related to the
puerperium
60
Indirect obstetric deaths
40
Obstetric death of unspecified cause
20 Maternal Deaths from from any obstetric
cause occurring more than 42 days but less
than one year after delivery and sequelae
0
2005 2006 2007 2008 2009
Source: PAHO/WHO. Mortality Information System
22. Belize
Mortality data base
(Direct Obstetric)
Data reported by the
country
http://health.gov.bz/www/attachments/565_annual%20report%202009-2011%20-%202.pdf
23. MMR with different
number of death
Year MMR Death
2008 86.2 13
2008 92.9 14
2007 106.0 16
2007 132.3 20
24. • Do we all use the same definition?
• Do we all agree on how to measure it?
• Do we use the same data collection
instrument for measurement?
• What do we want to measure?
25. Under-reporting of maternal Potential reasons cited for under
deaths was more common among reporting/misclassification include
the following the following
• Early pregnancy deaths, which •Inadequate understanding of ICD
cannot be linked to a reportable rules (either ICD-9 or ICD-10).
birth outcome.
• Death certificates completed
• Deaths in the later postpartum without mention of pregnancy
period (these were less likely to be
reported than early postpartum status.
deaths).
• Desire to avoid litigation.
• Deaths at extremes of maternal age
(youngest and oldest). • Desire to suppress information
(especially as related to abortion
• Miscoding by ICD-9 or ICD-10, most deaths).
often seen in cases of deaths
caused by:
––cerebrovascular diseases;
––cardiovascular diseases.
26. ¿Qué progresos y debilidades existen?
Panorama Heterogéneo en la Región
• Compromiso político de los países • Falta de empleo correcto de
definiciones internacionalmente
• Establecimiento de intervenciones aceptadas muerte materna obstétrica
directa e indirecta (CIE-10)
• Elaboración de informes de monitoreo
de avances de los países • Estimaciones por Agencias (diferentes
resultados para un país)
• Fortalecimiento de los sistemas de
información
• Inconsistencias en el indicador (RMM)
• Aplicación de metodologías para la
• Dificultad para el monitoreo y
búsqueda intencionada de muertes
maternas (Brasil, México, Paraguay) evaluación del avance de 1990 a 2010
• Involucramiento de la comunidad y • Desconocimiento de las verdaderas
organizaciones sociales causas de las muertes maternas